Cardiac Rehabilitation Maintenance Programs for Cardiovascular Disease
(EMPOWER ME Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Fully Automated Online Program, High Intensity Cardiac Rehabilitation Maintenance Program, Low-Intensity Cardiac Rehabilitation Maintenance Program, Text Messaging for Cardiovascular Disease?
Research shows that cardiac rehabilitation programs, which include exercise and lifestyle changes, can improve heart health and reduce the risk of future heart problems. Activity-monitoring devices and mobile apps can help patients stay active and improve health outcomes, suggesting that online and text-based programs might also be effective.12345
Is cardiac rehabilitation safe for humans?
Cardiac rehabilitation programs, which include exercise and other supportive activities, are generally considered safe and beneficial for people with heart disease. They have been shown to reduce the risk of future heart problems and improve overall health, with no significant safety concerns reported in the studies reviewed.678910
How is the cardiac rehabilitation maintenance program treatment different from other treatments for cardiovascular disease?
Cardiac rehabilitation maintenance programs are unique because they focus on long-term physical activity and lifestyle changes to maintain health after initial rehabilitation, unlike other treatments that may focus solely on medication or short-term interventions. These programs integrate physical activity with education and risk factor modification to reduce cardiovascular risk and improve quality of life.1011121314
What is the purpose of this trial?
The study is sponsored by the National Heart, Lung, and Blood Institute, which is part of the National Institutes of Health. We expect to enroll 400 subjects into this study. We will be recruiting research participants that are finishing or will finish cardiac rehabilitation soon. Participants belong to one or more groups of people who are less often studied in cardiac rehabilitation research, may have less access to a formal cardiac rehabilitation maintenance program, or they may especially benefit from additional support after cardiac rehabilitation ends. The main purposes of this study are to evaluate which treatments work the best after cardiac rehabilitation, which order to deliver the treatments in, and which treatments are as minimally burdensome as possible while still working well. This study will make two comparisons (one comparison between a set of low-intensity interventions and another between a set of higher-intensity interventions) to determine which produces the best behavioral adherence immediately after Phase II (outpatient) cardiac rehabilitation
Eligibility Criteria
This trial is for individuals finishing or soon to finish cardiac rehabilitation, particularly those from underrepresented groups in cardiac rehab research, with limited access to maintenance programs, or who may benefit from extra support post-rehab. Participants must meet certain health criteria.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Intervention
Participants receive either a low-intensity text messaging intervention or a fully automated online program for 2 months
Second Intervention
Non-responders to the initial intervention receive either low-intensity or high-intensity home-based cardiac rehabilitation for 3 months
Follow-up
Participants are monitored for adherence to cardioprotective behaviors and other outcomes
Treatment Details
Interventions
- Fully Automated Online Program
- High Intensity Cardiac Rehabilitation Maintenance Program
- Low-Intensity Cardiac Rehabilitation Maintenance Program
- Text Messaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Miriam Hospital
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Office of the Director, National Institutes of Health (OD)
Collaborator